Lamotrigine‐Associated Rash: Risk/Benefit Considerations in Adults and Children

Summary: Purpose: Lamotrigine (LTG) is an antiepileptic drug (AED) recently released in several countries. It is effective for a variety of seizure types in adults and children both as an add‐on agent and in monotherapy, and is generally well tolerated. This report reviews the apparent risk factors for rash associated with LTG to determine whether and how the risk of serious rash can be minimized in practice.

[1]  J. Messenheimer,et al.  Safety Review of Adult Clinical Trial Experience with Lamotrigine , 1998, Drug safety.

[2]  J. Motte,et al.  Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. , 1997, The New England journal of medicine.

[3]  J. Motte,et al.  Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. , 1997, The New England journal of medicine.

[4]  R. Mann,et al.  Safety of Long‐Term Lamotrigine in Epilepsy , 1997, Epilepsia.

[5]  R. Stern,et al.  Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: A record linkage study , 1997, Neurology.

[6]  M. Matsuura.  Psychosis of Epilepsy, with Special Reference to Anterior Temporal Lobectomy , 1997 .

[7]  S. Davis,et al.  Suspected Lamotrigine-Induced Toxic Epidermal Necrolysis , 1997, The Annals of pharmacotherapy.

[8]  M. Brodie,et al.  Lamotrigine substitution study: evidence for synergism with sodium valproate? , 1997, Epilepsy Research.

[9]  O. Dulac,et al.  Long-term safety and efficacy of lamotrigine (Lamictal®) in paediatric patients with epilepsy , 1997, Seizure.

[10]  K. Fogh,et al.  Toxic epidermal necrolysis after treatment with lamotrigine (Lamictal®) , 1997, Seizure.

[11]  H. Schuppe,et al.  Lamotrigine-induced Stevens-Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro. , 1997, Dermatology.

[12]  H. Schuppe,et al.  Lamotrigine and toxic epidermal necrolysis , 1996, The Lancet.

[13]  J. Sullivan,et al.  Lamotrigine‐induced toxic epidermal necrolysis treated with intravenous cyclosporin: A discussion of pathogenesis and immunosuppressive management , 1996, The Australasian journal of dermatology.

[14]  E. Wirrell,et al.  Lamotrigine-induced rash in children , 1996, Neurology.

[15]  E. Perucca.  Add-on trial of lamotrigine followed by withdrawal of concomitant medication and stabilization on monotherapy , 1996 .

[16]  F. Matsuo,et al.  Skin Rash Associated With Lamictal®: Incidence, Time To Onset, And Risk Factors: 6.51 , 1996 .

[17]  R. Stern,et al.  Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. , 1996, The New England journal of medicine.

[18]  O. Dulac,et al.  Lamotrigine for the treatment of epilepsy in childhood. , 1995, The Journal of pediatrics.

[19]  D. Schneider,et al.  Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. , 1995, International journal of clinical pharmacology and therapeutics.

[20]  K. Goa,et al.  Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. , 1995, Drugs.

[21]  L. Hughes-Davies,et al.  Severe adverse cutaneous reactions to drugs. , 1995, The New England journal of medicine.

[22]  S. Brown,et al.  Rechallenge with lamotrigine after initial rash , 1995, Seizure.

[23]  M. Brodie,et al.  Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy , 1995, The Lancet.

[24]  P. Uvebrant,et al.  Intractable Epilepsy in Children. The Efficacy of Lamotrigine Treatment, Including Non-Seizure-Related Benefits , 1994, Neuropediatrics.

[25]  R. Stern,et al.  Severe adverse cutaneous reactions to drugs. , 1994, The New England journal of medicine.

[26]  A. Richens.  Safety of Lamotrigine , 1994, Epilepsia.

[27]  R. Mattson,et al.  Lamotrigine Therapy for Partial Seizures: A Multicenter, Placebo‐Controlled, Double‐Blind, Cross‐Over Trial , 1994, Epilepsia.

[28]  J. Gotman,et al.  EEG Slow Waves and Memory Performance During the Intracarotid Amobarbital Test , 1994, Epilepsia.

[29]  T. Steiner.  Comparison of lamotrigine (Lamictal) and phenytoin monotherapy in newly diagnosed epilepsy [Abstract] , 1994 .

[30]  F. Matsuo,et al.  Placebo‐controlled study of the efficacy and safety of lamotrigine in patients with partial seizures , 1993, Neurology.

[31]  G. Baker,et al.  Outcomes of Add‐on Treatment with Lamotrigine in Partial Epilepsy , 1993, Epilepsia.

[32]  B. Weatherley,et al.  Sodium valproate acutely inhibits lamotrigine metabolism. , 1992, British journal of clinical pharmacology.

[33]  V. Anttila,et al.  Carbamazepine‐Induced Eosinophilic Colitis , 1992, Epilepsia.

[34]  R. Ramsay,et al.  Pharmacokinetics and safety of lamotrigine (Lamictal®) in patients with epilepsy , 1991, Epilepsy Research.

[35]  G. Schapel.  No effect of lamotrigine on carbamazepine and carbamazepine-epoxide concentrations , 1991 .

[36]  G. Goodwin,et al.  Controlled Trial of Lamotrigine (Lamictar) for Refractory Partial Seizures , 1989, Epilepsia.

[37]  C. Binnie,et al.  Acute Effects of Lamotrigine (BW430C) in Persons With Epilepsy , 1986, Epilepsia.

[38]  J. Simiand,et al.  Mechanism of anticonvulsant action of valproate , 1982, Progress in Neurobiology.